H.R. 2450 · 119th Congress · Health
Prescription Drug Transparency and Affordability Act
- IntroducedMar 27, 2025 Done
- CommitteeReferred to 3 committees Current stage
- House floorNot yet Not reached yet
- Senate floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill requires pharmacy benefit managers (PBMs) to report, at least once every six months, prescription drug pricing, payment, and utilization data to the health insurance plans for which the PBM provides services.
Specifically, a PBM contracted to provide services to an employer or sponsor offering a large group health insurance plan (i.e., a plan with at least 100 employees or participants) must report to the plan certain information for prescription drug claims under the plan. This includes, for each drug, the difference between the compensation paid by the plan to the PBM and the compensation paid by the PBM to the pharmacy.
Further, for each therapeutic class of drugs under the plan, a PBM must report (1) the total amount it received in rebates, fees, and discounts; and (2) the net spending for each class after such rebates, fees, and discounts.
Each PBM also must report certain information about (1) drugs for which total spending exceeded $10,000; and (2) drugs dispensed through pharmacies affiliated with the plan or PBM, such as the percentage of prescriptions dispensed by such affiliates.
Finally, a PBM providing services to any group health insurance plan must provide the plan with a summary document that includes similar information for prescription drug claims under the plan, as determined by the Department of Health and Human Services. Plans must also make certain aggregate summary information available to plan participants.
PBMs and plans that violate these requirements are subject to civil penalties.
Congressional Research Service · summary of “Introduced in House” version · Mar 27, 2025
Who lobbies on it
5 organizations, more than 93% of House bills · 18 filings · Q1 2025–Q3 2026These 5 organizations’ PACs gave $16.5K to 4 of the 4 members sponsoring or cosponsoring H.R. 2450 in the 2025–26 election cycle.
One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
America's Health Insurance Plans Inc (ahip)
7 of 7 quarters
“…H.R. 2450 - Prescription Drug Transparency and Affordability Act - Rep. McDonald Rivet, Kristen - PBM transparency H.R. 3493 - Global Fairness in Drug Pricing Act - Rep. Khanna, Ro - Prescription drug international reference pricing H.R. 3546 - Prescription Drug Price Relief Act - Rep. Khanna, Ro - Prescription drug…”
$11.3M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Boeing Company
6 of 7 quarters
“H.R.1162 - Medicaid Primary Care Improvement Act. S.1944 - Employee Access to Worksite Health Services Act. H.R.2450 - Prescription Drug Transparency and Affordability Act. S.2355 & H.R.5582 - Patients Deserve Price Tags Act. H.R.2199 & S.1173 - Restore Protections for Dialysis Patients Act. Implementation of P.L.…”
$7.9M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Pharmaceutical Care Management Association
3 of 7 quarters
“…H.R. 2450; Prescription Drug Transparency and Affordability Act H.R. 3164; Ensuring Community Access to Pharmacist Service Act H.R. 3269; Eliminating Thickets to Increase Competition Act S.2276; Eliminating Thickets to Increase Competition Act H.R. 2214; Delinking Revenue from Unfair Gouging Act S.864: Help Ensure…”
$13.7M lobbying spend in 2025, all issuesQ3 2025 filing
2 more organizations, every filingPROUpgrade
Organizations that named H.R. 2450 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
2 actions · newest first- Mar 27, 2025Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Mar 27, 2025Introduced in House